FDL169 is a CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.

Status

Phase 1 studies to test the safety of FDL169 in people with CF were completed in Europe. No further development in CF is planned at this time.

Sponsor

This program was sponsored by Flatley Discovery Lab.